Advertisement
Home Tags Blood Disorders

Tag: Blood Disorders

Benralizumab Noninferior to Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis

Benralizumab is noninferior, but not superior, for adults with eosinophilic granulomatosis with polyangiitis receiving standard care

Rusfertide Treatment Beneficial for Patients With Polycythemia Vera

Rusfertide reduces number of phlebotomies and maintains hematocrit at less than 45 percent

Outcomes Similar for Therapy-Related, De Novo MDS After Haplo-HSCT

Three-year overall and disease-free survival, three-year cumulative incidence of relapse similar between the groups

Oral Switch Noninferior for Low-Risk S. Aureus Bloodstream Infection

Early oral antimicrobial therapy noninferior to intravenous standard therapy for low-risk bloodstream infection

FDA Approves Casgevy to Treat Beta-Thalassemia

Casgevy is the first CRISPR-based medicine to be approved for use in the United States

Imetelstat Leads to Durable Red Blood Cell Transfusion Independence

Findings seen in heavily transfused patients with lower-risk myelodysplastic syndromes

American Society of Hematology, Dec. 9 to 12

By Beth Gilbert HealthDay Reporter The annual meeting of the American Society of Hematology was held from Dec. 9 to 12 in San Diego and...

Hematocrit Within Normal Range With Testosterone Gender-Affirming Therapy

Mean hematocrit ranged from 41.84 to 45.68 percent for those receiving testosterone as gender-affirming hormone therapy

FDA Approves First Treatment for Congenital Thrombotic Thrombocytopenic Purpura

The genetically engineered protein product is safe, effective for the rare inherited blood clotting disorder

Tolerable Treatments Lacking for Higher-Risk Myelodysplastic Syndromes

61 percent of 200 patients with higher-risk MDS were subsequently hospitalized within six months of diagnosis